drugset / Trial / NCT00319111

Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT00319111

Phase 3 Completed 151 enrolled Actelion
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.

Timeline

Start
2006-01
Primary completion
2009-02
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 62.5 mg Oral
Subject Bosentan Other / unclassified 125 mg Oral